Sugi Predict

Sugi Predict / Compounds / SCHEMBL850747

SCHEMBL850747

SCHEMBL850747

COC(=O)c1ccc(CC(F)(F)F)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 1/20 0.59
▸ CYP4A11 Q02928 2/20 0.54
▸ CYP4F2 P78329 1/20 0.53
▸ CA1 P00915 4/20 0.52
▸ CA2 P00918 4/20 0.52
▸ TDP1 Q9NUW8 1/20 0.52
▸ CA12 O43570 1/20 0.52
▸ CA7 P43166 1/20 0.52
▸ CA9 Q16790 1/20 0.52
▸ CA14 Q9ULX7 1/20 0.52
▸ MAPT P10636 2/20 0.52
▸ PTPRB P23467 1/20 0.50
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ MAPK1 P28482 2/20 0.49
▸ TSHR P16473 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ NPC1 O15118 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20714604 0.84 LOXL2 (0.54) LOXL2CYP4A11CYP4F2CA1CA2
SCHEMBL9917356 0.83 LOXL2 (0.61) LOXL2CYP4A11CYP4F2CA1CA2
SCHEMBL8337316 0.82 CYP4A11 (0.60) LOXL2CYP4A11CYP4F2CA1CA2
SCHEMBL27970865 0.81 ALDH1A1 (0.41) LOXL2CYP4A11CYP4F2PTPRBMEN1
SCHEMBL27936929 0.81 LOXL2 (0.42) LOXL2CYP4A11CYP4F2MAPTPTPRB
SCHEMBL27970796 0.81 ALDH1A1 (0.41) LOXL2CYP4A11CYP4F2PTPRBMEN1
SCHEMBL10661402 0.80 LOXL2 (0.62) LOXL2CYP4A11CYP4F2CA1CA2
SCHEMBL7166555 0.80 LOXL2 (0.58) LOXL2CYP4A11CYP4F2CA1CA2
SCHEMBL10144968 0.80 LOXL2 (0.64) LOXL2CYP4A11CYP4F2MAPTPTPRB
SCHEMBL880015 0.80 CYP4A11 (0.66) LOXL2CYP4A11CYP4F2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 — — US disclosed
US-11667606-B2 Thyromimetics AUTOBAHN THERAPEUTICS, INC. (US) 2023-06-06 — — US disclosed
US-20220047540-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORP (FI) 2022-02-17 — — US disclosed
CN-113784950-A Novel thyromimetic agents 速通医疗公司 2021-12-10 — — CN disclosed
US-20210053917-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2021-02-25 — — US disclosed
US-20210053917-A1 NOVEL THYROMIMETICS AUTOBAHN THERAPEUTICS, INC. 2021-02-25 — — US disclosed
US-20200352898-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORP (FI) 2020-11-12 — — US disclosed
CN-105873925-B Antiparasitic and insecticidal isoxazoline compounds 勃林格殷格翰动物保健美国公司 2019-09-10 — — CN disclosed
US-20190029990-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORP (FI) 2019-01-31 — — US disclosed
US-10155739-B2 Halogenated S-(perfluoroalkyl)dibenzothiophenium salt and its production methods ZHEJIANG JIUZHOU PHARM CO LTD (CN) 2018-12-18 — — US disclosed
CN-104334525-A Catechol o-methyltransferase activity inhibiting compounds ORION CORP 2015-02-04 — — CN disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 — — EP disclosed
EP-2433940-B1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2014-09-24 — — EP disclosed
WO-2013175053-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS ORION CORPORATION (FI) 2013-11-28 — — WO disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2012-10-25 — — US disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 — — EP disclosed
EP-2433940-A1 SPIROIMIDAZOLONE DERIVATIVE Chugai Seiyaku Kabushiki Kaisha (JP) 2012-03-28 — — EP disclosed
WO-2010126030-A1 SPIROIMIDAZOLONE DERIVATIVE 中外製薬株式会社 (JP) 2010-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11667606-B2 Thyromimetics TPO, TSHR, TTR LOXL2 1761/4885CYP4A11 320/4885CYP4F2 120/4885
US-20120270838-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 LOXL2 4771/4885CYP4A11 328/4885CYP4F2 2161/4885
US-10155739-B2 Halogenated S-(perfluoroalkyl)dibenzothiophenium salt and its production methods FGFR2, SULT1A1, PFAS LOXL2 4003/4885CYP4A11 475/4885CYP4F2 74/4885
US-20200352898-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS COMT, PNMT, HNMT LOXL2 2336/4885CYP4A11 106/4885CYP4F2 74/4885
US-20190029990-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS COMT, PNMT, HNMT LOXL2 2336/4885CYP4A11 106/4885CYP4F2 74/4885
US-20210053917-A1 NOVEL THYROMIMETICS TPO, TSHR, CHRM1 LOXL2 1580/4885CYP4A11 302/4885CYP4F2 142/4885
US-20220047540-A1 CATECHOL O-METHYLTRANSFERASE ACTIVITY INHIBITING COMPOUNDS COMT, PNMT, HNMT LOXL2 2336/4885CYP4A11 106/4885CYP4F2 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.